Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Holds 300 Validated Medicare Rx Formularies As Submission Deadline Nears

This article was originally published in The Pink Sheet Daily

Executive Summary

The original deadline for Part D formularies was extended until April 22 for the benefit of potential sponsors, not because the agency is falling behind schedule, CMS' Tudor says. Caremark and PacifiCare execs question why the deadline was moved.

You may also be interested in...

CMS Extends Part D Formulary Deadline

The Centers for Medicare & Medicaid Services is extending the deadline for submitting Medicare Part D drug plan formularies to the agency

Medicare Rx Plan Numbers Will Not Match Card Sponsor Totals, CMS’ McClellan Predicts

Seniors will not be overwhelmed by a high number of plan choices, the agency administrator maintains. CMS has received a large volume of Part D applications, but not all look “complete and serious,” McClellan indicates.

Endo’s Lidoderm Mailings Draw FDA Warning Letter For Unsubstantiated Claims

FDA asks Endo to disseminate “corrective messages” to doctors who received the violative promotional materials, which the agency says omit risk information and contain unsubstantiated effectiveness claims.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts